logo
Harvard thought it had a cheap copy of the Magna Carta. It turned out to be extremely rare

Harvard thought it had a cheap copy of the Magna Carta. It turned out to be extremely rare

CTV News15-05-2025

This photo provided by Harvard Law School shows a rare copy of the Magna Carta from 1300 sits in a display case on April 15, 2025, at Harvard Law School in Cambridge, Mass. (Lorin Granger/Harvard Law School via AP)
BOSTON — Harvard University for decades assumed it had a cheap copy of the Magna Carta in its collection, a stained and faded document it had purchased for less than US$30.
But two researchers have concluded it has something much more valuable — a rare version from 1300 issued by Britain's King Edward I.
The original Magna Carta established in 1215 the principle that the king is subject to law, and it has formed the basis of constitutions globally. There are four copies of the original and, until now, there were believed to be only six copies of the 1300 version.
'My reaction was one of amazement and, in a way, awe that I should have managed to find a previously unknown Magna Carta,' said David Carpenter, a professor of medieval history at King's College London. He was searching the Harvard Law School Library website in December 2023 when he found the digitized document.
'First, I'd found one of the most rare documents and most significant documents in world constitutional history,' Carpenter said. 'But secondly, of course, it was astonishment that Harvard had been sitting on it for all these years without realizing what it was.'
Confirming the document's authenticity
Carpenter teamed up with Nicholas Vincent, a professor of medieval history at Britain's University of East Anglia, to confirm the authenticity of Harvard's document.
Comparing it to the other six copies from 1300, Carpenter found the dimensions matched up. He and Vincent then turned to images Harvard librarians created using ultraviolet light and spectral imaging. The technology helps scholars see details on faded documents that are not visible to the human eye.
That allowed them to compare the texts word-for-word, as well as the handwriting, which include a large capital 'E' at the start in 'Edwardus' and elongated letters in the first line.
After the 1215 original printed by King John, five other editions were written in the following decades — until 1300, the last time the full document was set out and authorized by the king's seal.
The 1300 version of Magna Carta is 'different from the previous versions in a whole series of small ways and the changes are found in every single one,' Carpenter said.
Harvard had to meet a high bar to prove authenticity, Carpenter said, and it did so 'with flying colors.'
Its tattered and faded copy of the Magna Carta is worth millions of dollars, Carpenter estimated — though Harvard has no plans to sell it. A 1297 version of the Magna Carta sold at auction in 2007 for $21.3 million.
A document with a colourful history
The other mystery behind the document was the journey it took to Harvard.
That task was left to Vincent, who was able to trace it all the way back to the former parliamentary borough of Appleby in Westmorland, England.
The Harvard Law School library purchased its copy in 1946 from a London book dealer for $27.50. At the time, it was wrongly dated as being made in 1327.
Vincent determined the document was sent to a British auction house in 1945 by a World War I flying ace who also played a role defending Malta in World War II. The war hero, Forster Maynard, inherited the archives from Thomas and John Clarkson, who were leading campaigners against the slave trade. One of them, Thomas Clarkson, became friends with William Lowther, hereditary lord of the manor of Appleby, and he possibly gave it to Clarkson.
'There's a chain of connection there, as it were, a smoking gun, but there isn't any clear proof as yet that this is the Appleby Magna Carta. But it seems to me very likely that it is,' Vincent said. He said he would like to find a letter or other documentation showing the Magna Carta was given to Thomas Clarkson.
Making Magna Carta relevant for a new generation
Vincent and Carpenter plan to visit Harvard in June to see its Magna Carta firsthand — and they say the document is as relevant as ever at a time when Harvard is clashing with the Trump administration over how much authority the federal government should have over its leadership, admissions and activism on campus.
'It turns up at Harvard at precisely the moment where Harvard is under attack as a private institution by a state authority that seems to want to tell Harvard what to do,' Vincent said.
It also is a chance for a new generation to learn about the Magna Carta, which played a part in the founding of the United States — from the Declaration of Independence to the adoption of the Bill of Rights. Seventeen states have incorporated aspects of it into their laws.
'We think of law libraries as places where people can come and understand the underpinnings of democracy,' said Amanda Watson, the assistant dean for library and information services at Harvard Law School. 'To think that Magna Carta could inspire new generations of people to think about individual liberty and what that means and what self-governance means is very exciting.'
Michael Casey, The Associated Press

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Globe and Mail

time38 minutes ago

  • Globe and Mail

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors. 'Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board,' said Paul Clancy, chair of the board of directors of Xilio Therapeutics. 'With over 25 years of experience in oncology research and development, focused on translational medicine and clinical pharmacology at BMS and Pfizer, we look forward to benefitting from Tunde's extensive expertise as we advance toward the clinic with XTX501, our masked PD-1/IL-2 bi-specific, and our bi-specific and tri-specific masked T cell engager programs.' 'Xilio's innovative approach to developing tumor-activated immuno-oncology therapies presents an exciting opportunity to advance novel molecules, which hold the potential to overcome the limitations of current cancer treatments,' said Dr. Bello. 'I am honored to join Xilio's board of directors at this important time and look forward to contributing to Xilio's efforts to meaningfully improve outcomes for patients while minimizing systemic toxicities.' Akintunde Bello, Ph.D. Dr. Bello brings more than 25 years of oncology drug development and leadership experience to Xilio, with deep expertise in early translational medicine and clinical pharmacology across complex biologics and immunotherapies, including anti-CTLA-4 and PD-1 checkpoint inhibitors, T cell engagers and tumor-selective molecules. He most recently served as senior vice president, head of clinical pharmacology, pharmacometrics and bioanalysis at Bristol Myers Squibb Company (BMS) until his retirement in 2025. While at BMS, Dr. Bello oversaw clinical pharmacology and pharmacometrics across multiple therapeutic areas. Prior to BMS, Dr. Bello spent more than a decade with Pfizer Inc. (Pfizer), where he was responsible for overseeing clinical pharmacology for Pfizer's late-stage oncology development programs. Dr. Bello received a in biomedical sciences from Portsmouth Polytechnic, an in instrumentation and analytical science from University of Manchester and a Ph.D. in pharmaceutical sciences from King's College, University of London. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting and follow us on LinkedIn (Xilio Therapeutics, Inc). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding achievement of key milestones; and the potential benefits of any of Xilio's current or future product candidates in treating patients; and Xilio's strategy, goals, business plans and focus. The words 'aim,' 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'seek,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, general market conditions; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio's current or future product candidates; Xilio's ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio's advancement of multiple early-stage immune cell engager programs; interim or preliminary preclinical or clinical data or results, which may not be replicated in or predictive of future preclinical or clinical data or results; Xilio's ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio's product candidates, which may not support further development of such product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of current or future clinical trials; Xilio's ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio's ability to obtain and maintain sufficient cash resources to fund its operations; the impact of international trade policies on Xilio's business, including U.S. and China trade policies; Xilio's ability to maintain its clinical trial collaboration with Roche to develop vilastobart in combination with atezolizumab; and Xilio's ability to maintain its collaboration and partnership agreements with Gilead and AbbVie. These and other risks and uncertainties are described in greater detail in the sections entitled 'Risk Factor Summary' and 'Risk Factors' in Xilio's filings with the U.S. Securities and Exchange Commission (SEC), including Xilio's most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Astronomy show accidentally reveals unseen structure in our solar system
Astronomy show accidentally reveals unseen structure in our solar system

CTV News

time3 hours ago

  • CTV News

Astronomy show accidentally reveals unseen structure in our solar system

The Oort Cloud, an expanse of icy bodies in the far reaches of our solar system, is shown here in a scene from "Encounters in the Milky Way," a show at New York City's Hayden Planetarium that spawned an accidental discovery about the cloud's shape. AMNH via CNN Newsource An accidental discovery might change how we think about one of the most mysterious structures in our solar system. The Oort Cloud, a large expanse of icy bodies revolving around the sun at a distance 1,000 times greater than the orbit of Neptune, is widely thought to be spherical — although it has never been directly observed. But during the preproduction of a show titled 'Encounters in the Milky Way,' which debuted Monday at the Hayden Planetarium in New York City, a projection on the planetarium's dome revealed something strange within the Oort Cloud: a spiral. The curators were testing out a scene in September that includes a detailed view of Earth's celestial neighborhood — from the sun to the solar system's outer edges — and were surprised when they saw the structure, which looked coincidentally similar to a spiral galaxy such as our own. 'We hit play on the scene, and immediately we saw it. It was just there,' recalled Jackie Faherty, an astrophysicist at the American Museum of Natural History and the curator of the show. 'I was confused and thought that was super weird. I didn't know if it was an artifact, I didn't know if it was real.' To investigate, Faherty got in touch with David Nesvorny, an institute scientist with the Southwest Research Institute in Boulder, Colorado, and the Oort Cloud expert who had provided scientific data for the scene. 'We didn't create it — David did,' Faherty said. 'This is David's simulation, and it's grounded in physics. It has a totally good physical explanation for why it should be there.' At first, Nesvorny suspected artifacts — abnormalities or distortions in the data visualization — but once he looked at his data, he confirmed the presence of the spiral and eventually published a scientific paper about the discovery in April in The Astrophysical Journal. 'Weird way to discover things,' he said. 'I should know my data better, after years of working with it.' Crazy, long orbits The existence of the Oort Cloud was first proposed in 1950 by Dutch astronomer Jan Oort, who imagined it as a shell of icy bodies swirling around the sun from up to 1.5 light-years away. The cloud is the most distant region in our solar system, stretching as much as halfway to the next star, according to NASA. Spiral structure The spiral structure, visible here behind the sun in a scene from the show, surprised scientists and animators when they saw it projected on the planetarium's dome during preproduction. AMNH via CNN Newsource It's composed of leftovers from the making of our solar system, which were scattered in every direction by the planets after they formed. That means many of the icy bodies in the Oort Cloud don't share the same orbital plane as the solar system itself but travel at various inclinations, which is why the Oort Cloud is pictured as a sphere. If one of those icy bodies gets flung inward toward the sun, the heat starts vaporizing some of the material in the body, creating a tail — and what we call a comet. 'Every now and again, some of these icy bodies come into the inner solar system, and we can see the orbit that they're on,' Faherty said. 'And they're on these really crazy, long orbits. It can take them millions of years to go around the sun. And when they come in, they help us understand how far away they may have come from.' The problem with trying to imagine what the Oort Cloud looks like is that scientists have never seen it, even though we are technically surrounded by it. That's because the bodies that make it up are small — fewer than 60 miles (97 kilometers) in diameter — and even though they potentially number in the trillions, they are far away, making observations with telescopes difficult. The spiral was hiding in Nesvorny's data because he had never thought of visualizing it three-dimensionally. 'I never looked at it in Cartesian coordinates — I didn't have a good reason to do so,' he said. 'But once you do that, it's obvious. It's there.' The galactic tide To confirm the findings, Nesvorny used one of the most powerful computers in the world, NASA's Pleiades Supercomputer, to run simulations that took weeks to complete. 'I thought, maybe just this particular simulation (I gave the planetarium) is showing it, and all the other simulations with other stellar encounters, other parameters, will not show it, in which case it wouldn't be so interesting,' he said. 'But all the simulations, all the models I have, show the spiral.' The reason it's there, he said, is that objects in the Oort Cloud are far away enough from the sun's gravity that they also start being affected by the galactic tide — the gravitational field of our galaxy, exerted by the stars and the dark matter in it. This field is acting on the small bodies and comets in the Oort Cloud by twisting their orbital planes to create a spiral. The spiral, Nesvorny added, is in the inner part of the Oort Cloud, the closest to us, and he still believes that the outer portion is spherical or shell-shaped. The problem of observing the Oort Cloud remains, even though the Vera C. Rubin Observatory, a powerful telescope that recently came online in Chile, could offer a hand by discovering and observing individual icy bodies in the cloud. However, according to Nesvorny, the telescope will likely discover dozens of these bodies — not the hundreds that would be required to produce a meaningful visualization of the spiral. The spiral theory helps to illuminate the dynamics of our solar system, according to Faherty. 'If you're going to come up with a theory of how solar systems evolve, you should take into account the kind of shapes you might have in their structure,' she said. 'Maybe comets helped deliver water to Earth. Maybe the building blocks of life could be out there in the Oort Cloud, so if you want to talk about the potential building blocks of life that surround our solar system, you need to understand its shape.' Vera C. Rubin Observatory The Vera C. Rubin Observatory, located in the Tololo hill near La Serena, Chile, will survey the night sky during its 10-year mission and could greatly expand scientists' understanding of the Oort Cloud. Javier Torres/AFP/Getty Images via CNN Newsource It's a 'dream,' she added, to be able to present science so recent in a show aimed at the general public. 'I truly believe that the planetarium, the dome itself, is a research tool,' Faherty said. 'I like to say that this is science that hasn't had time to reach your textbook yet.' Viewing what's not visible The spiral finding is a wonderful example of just how much we can learn through visualizing the universe in new ways, said Malena Rice, an assistant professor of astronomy at Yale University who did not participate in the study. 'This result reshapes our mental image of our home solar system, while also providing a new sense for what extrasolar systems' Oort clouds may look like,' Rice added. 'It unites our models of the solar system with what we know about the broader galaxy, placing it into context as a dynamic system. We are not static, and we are not isolated — our solar system is shaped by its broader ecosystem, and the Oort spiral exemplifies that.' While the paper is interesting, it is almost entirely theoretical, as it is based on numerical simulations of the interactions between the sun's gravity and the gravitational pull of the rest of the Milky Way galaxy's motion, said Edward Gomez, an astrophysicist and honorary lecturer at Cardiff University in the UK. He also was not involved with the study. 'Long period comets enter the inner solar system at a range of angles, which the authors try to model using their spiral arm idea,' Gomez said in an email. 'What they are proposing could be true, but it could also be modelled by other shapes of the Oort cloud or physical processes. How to test this is their major issue, because only a handful of potential Oort cloud objects are known about.' Confirming the findings will be a challenge, noted Simon Portegies Zwart, a professor of numerical star dynamics at Leiden University in the Netherlands who was not part of the team behind the research. 'It is interesting that they found the spiral, (but) it seems unlikely that we are going to witness (it) in the foreseeable future,' he said. With luck, he added, the Vera Rubin observatory will detect a few hundred inner Oort Cloud objects, but the spiral would only be visible if many more are found: 'It therefore seems unlikely to be a clearly detectable structure.'

EDETEK Engages Capgemini to Support Its Global Transformation Initiative and Accelerate AI Innovation in Clinical Development
EDETEK Engages Capgemini to Support Its Global Transformation Initiative and Accelerate AI Innovation in Clinical Development

National Post

time6 hours ago

  • National Post

EDETEK Engages Capgemini to Support Its Global Transformation Initiative and Accelerate AI Innovation in Clinical Development

Article content NEW YORK — EDETEK Inc., a global provider of leading AI-driven clinical development platforms and services, has engaged Capgemini to support its ongoing advancements in digital transformation within the life sciences industry. This engagement combines EDETEK's deep domain expertise and established platforms and services with Capgemini's advanced AI and engineering capabilities, to enable EDETEK to deliver innovative solutions aimed at optimizing clinical development, improving operational efficiency, and accelerating the time-to-market for new therapies. Article content A shared vision for the future of clinical R&D Article content Article content By integrating advanced digital and data capabilities—including generative AI—across all phases of clinical trials, the project will support new efficiencies for pharmaceutical companies, including: Article content Dramatically reduce time-to-market for new therapies. Enablement of self-learning, insight-driven trials for faster, more proactive decision-making. Streamlined data management and trial workflows, enhancing efficiency and precision. Significant cost reductions and boosted drug pipeline value. Article content 'Working with Capgemini signifies our continuing efforts to expand our global capabilities towards delivering more effective and faster clinical development,' Article content said Dr. Shakthi Kumar, Chief Strategy & Business Officer at EDETEK. Article content 'By bringing together our AI-driven platforms with Capgemini's leading capabilities in life science and technology, we will empower life science organizations to conduct smarter, faster, and more predictive clinical trials—ultimately improving patient outcomes at scale.' Article content Bringing innovation to clinical development at scale Article content The engagement combines EDETEK's proven technology with Capgemini's global network and deep domain knowledge to scale AI-powered clinical innovation across the pharmaceutical industry. Together, this will help make intelligent, agile, and data-driven clinical trials accessible to more life sciences organizations worldwide. In addition, Capgemini will leverage its robust engineering capabilities to help scale EDETEK's platforms globally and enable continued leadership in reliability, innovation, and performance. Article content 'Our deep expertise in next-gen clinical development methodologies and advanced AI will expand EDETEK's R&D cloud and eClinical platform, helping its clients to unlock new levels of agility, insight, and efficiency,' Article content said Thorsten Rall, Global Industry Head, Life Sciences at Capgemini. 'Together, we are committed to redefining what's possible for the industry—delivering measurable value, accelerating innovation, and shaping the future of healthcare through smarter, more predictive clinical trials.' Article content About EDETEK, Inc. Article content Founded in 2009, EDETEK delivers high-quality AI-powered platforms and clinical services to over one hundred biopharma clients worldwide. With a presence across four continents, EDETEK is redefining the future of clinical development through intelligent technology. Article content For more information about EDETEK, please visit About Capgemini Capgemini is a global business and technology transformation partner, helping organizations to accelerate their dual transition to a digital and sustainable world, while creating tangible impact for enterprises and society. It is a responsible and diverse group of 340,000 team members in more than 50 countries. With its strong over 55-year heritage, Capgemini is trusted by its clients to unlock the value of technology to address the entire breadth of their business needs. It delivers end-to-end services and solutions leveraging strengths from strategy and design to engineering, all fueled by its market leading capabilities in AI, generative AI, cloud and data, combined with its deep industry expertise and partner ecosystem. The Group reported 2024 global revenues of €22.1 billion. Article content Article content Article content Contacts Article content Capgemini press contact: Article content Article content Julia Zimmerman Article content Article content Tel.:+1 847-922-7951 Article content Article content EDETEK press contact: Article content Article content Wei Kong Article content Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store